Literature DB >> 18330000

Which anesthetic should be used in the treatment of refractory status epilepticus?

Andrea O Rossetti1.   

Abstract

While the treatment of refractory status epilepticus (SE) relies on the use of anesthetic agents, mostly barbiturates, propofol, or midazolam, the study of the available literature discloses that the evidence level is low. Therapeutic coma induction appears straightforward for generalized convulsive or subtle SE, but this approach is debated for complex partial SE. Each anesthetic has its own advocates, and specific advantages and risks; furthermore, several different protocols have been reported regarding the duration and depth of sedation. However, it seems that the biological background of the patient (especially the etiology) remains the main prognostic determinant in SE. There is a clear need of controlled trials regarding this topic.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18330000     DOI: 10.1111/j.1528-1167.2007.01350.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  10 in total

Review 1.  Management of refractory status epilepticus in adults: still more questions than answers.

Authors:  Andrea O Rossetti; Daniel H Lowenstein
Journal:  Lancet Neurol       Date:  2011-10       Impact factor: 44.182

2.  Recent and future advances in the treatment of status epilepticus.

Authors:  Felix Rosenow; Susanne Knake
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

3.  Treatment of Convulsive Status Epilepticus.

Authors:  Eric H Grover; Yara Nazzal; Lawrence J Hirsch
Journal:  Curr Treat Options Neurol       Date:  2016-03       Impact factor: 3.598

4.  Robust control of burst suppression for medical coma.

Authors:  M Brandon Westover; Seong-Eun Kim; ShiNung Ching; Patrick L Purdon; Emery N Brown
Journal:  J Neural Eng       Date:  2015-05-28       Impact factor: 5.379

5.  Guidelines for the evaluation and management of status epilepticus.

Authors:  Gretchen M Brophy; Rodney Bell; Jan Claassen; Brian Alldredge; Thomas P Bleck; Tracy Glauser; Suzette M Laroche; James J Riviello; Lori Shutter; Michael R Sperling; David M Treiman; Paul M Vespa
Journal:  Neurocrit Care       Date:  2012-08       Impact factor: 3.210

6.  Calculating the risk benefit equation for aggressive treatment of non-convulsive status epilepticus.

Authors:  Matthew Ferguson; Matt T Bianchi; Raoul Sutter; Eric S Rosenthal; Sydney S Cash; Peter W Kaplan; M Brandon Westover
Journal:  Neurocrit Care       Date:  2013-04       Impact factor: 3.210

7.  Bowel ischemia: a rare complication of thiopental treatment for status epilepticus.

Authors:  Carlo Cereda; Mette M Berger; Andrea O Rossetti
Journal:  Neurocrit Care       Date:  2008-11-25       Impact factor: 3.210

Review 8.  Pharmacotherapy for Status Epilepticus.

Authors:  Eugen Trinka; Julia Höfler; Markus Leitinger; Francesco Brigo
Journal:  Drugs       Date:  2015-09       Impact factor: 9.546

Review 9.  Grand Rounds: An Update on Convulsive Status Epilepticus.

Authors:  Michael Kinney; John Craig
Journal:  Ulster Med J       Date:  2015-05

Review 10.  Propofol versus thiopental sodium for the treatment of refractory status epilepticus.

Authors:  Hemanshu Prabhakar; Mani Kalaivani
Journal:  Cochrane Database Syst Rev       Date:  2017-02-03
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.